Inventory: A selection of Lancet studies on November 21, 2020

1. The benefits of fat-lowering treatment for people over 75 years of age DOI: https://doi.org/10.1016/S0140-6736 (20) 32332-175 years of age the clinical benefits of LDL cholesterol reduction treatment are still controversial, researchers recently conducted a systematic review and meta-analysis aimed at summarizing the evidence of LDL cholesterol reduction treatment in elderly patients.
researchers searched the MEDLINE and Embase databases, published between March 1, 2015 and August 14, 2020, about any LDL cholesterol-lowering drug to cardiovascular The randomized controlled trial, which was the end of the event, analyzed the risk ratio (RR) of the major vascular events (cardiovascular death, myocardial infarction, or other acute coronary syndrome, stroke, or coronary artery hemodulation reconstruction) for each reduction of 1 mmol/L L L L LDL cholesterol.
a total of 6 documents that met the requirements were retrieved, including 1 meta-analysis (including 24 studies) and 5 individual trial papers, for a total of 244,090 patients, of whom 21,492 (8.8%) were over 75 years of age, of whom 11,750 (8.8%) 54.7 per cent received statins, 6209 (28.9 per cent) received ecstasy and 3,533 (16.4 per cent) received PCSK9 inhibitors, with an average follow-up time of 2.2 to 6.0 years.
study confirmed that reducing LDL cholesterol significantly reduced the risk of major vascular events (n-3519) in older adults, and that for every 1 mmol/L decrease in LDL cholesterol, the risk of cardiovascular events decreased by 26% (RR 0.74) in the over-75 population, comparable to that of people under 75 years of age (0.85).
effects of statins (0.82) and non-statins (0.67) were not significant.
the benefits of LDL cholesterol reduction in older patients, including a reduced risk of cardiovascular death (0.85), myocardial infarction (0.80), stroke (0.73) and coronary artery hemodynamic reconstruction (0.80).
effects of LDL elevation on myocardial infarction and atherosclerotic cardiovascular disease event risk in people aged 70-100 DOI:https://doi.org/10.1016/S0140- The results of previous studies at 6736 (20) 32233-9 showed that elevated LDL cholesterol was not associated with an increased risk of myocardial infarction and atherosclerosis cardiovascular disease in patients over 70 years of age, a view researchers recently tested among people aged 70-100.
CGPS study, baseline-free atherosclerosis cardiovascular disease or diabetes, and volunteers who did not take statins were involved in the study and received standard LDL cholesterol measurements.
study calculated the risk ratio (Hrs) and absolute event rates of myocardial infarction and atherosclerosis cardiovascular disease in participants, and estimated the number of treatments (NNT) required to prevent an event within five years.
a total of 91,131 volunteers participated in the study, with an average follow-up of 7.7 years, with a total of 1,515 people suffering from acute myocardial infarction for the first time and 3,389 with atherosclerotic cardiovascular disease.
the total population, for every 1.0 mmol/L increase in LDL levels, the risk of myocardial infarction was 1.34 and the risk ratio of atherosclerosis cardiovascular disease was 1.16.
For people aged 80-100, if LDL levels were 5.0 mmol/L or higher (e.g. familial hypercholesterolemia), the risk of myocardial infarction was 2.99 compared to those with LDL levels below 3.0 mmol/L, compared to 1.82 for those aged 70-79.
For people aged 70-100, for every 1.0 mmol/L increase in LDL levels, the most incidents of myocardial infarction and atherosclerotic cardiovascular disease per 1000 follow-up years were reported, and the lower the age, the fewer incidents occurred.
Among all ages, people aged 70-100 needed the least NNT to prevent a heart attack and atherosclerosis cardiovascular disease under moderate doses of statin prevention, while younger people needed more NNT.
: The effects of oxygen preservation on the prognosis and kidney function of transplant patients DOI: https://doi.org/10.1016/S0140-6736 (20)32411-9 The preservation of kidney feeds for transplantation is generally under cold, low oxygen conditions.
oxygen during preservation may reduce kidney damage and improve post-transplant results.
recently examined the effects of oxygen supplementation during low-temperature machine perfusion (HMP) on the prognostication of kidney transplant patients.
This randomized, double-blind, matching Phase III clinical study was conducted at 19 transplant centers in Europe, with kidney donors from donors aged 50 or over, and after the donor's circular death, two kidneys were transplanted into two different recipients, one of whom had HMP oxygen preservation (HMPO2 group) and the other with anaerobic preservation (HMP group).
of the study was a difference in EGFR in patients with 12 months of subjects.
106 patients were involved in the study.
12 months, the average EGFR for the HMPO2 group was 50.5 mL/min/1.73m2, while the HMP group was 46.7 mL/min/1.73m2.
HMPO2 group had fewer serious complications (Clavien-Dindo IIIb and above, 11% vs 16%) and a lower transplant failure rate (3% vs 10%, HR s 0.27).
MedSci Original Source: MedSci Original Copyright Notice: All text, images and audio and video materials on this website that state "Source: Mets Medicine" or "Source: MedSci Originals" are owned by Mets Medicine and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here